Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | OGA | O60502 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20038256 | 0.87 | MAP4K4 (0.41) | CHRNB2CHRNA4MAP4K4PDE10ACHRNB4 | |
| SCHEMBL20255203 | 0.83 | PDE10A (0.40) | KMT2AOGAPDE10A | |
| SCHEMBL20037726 | 0.79 | MAP4K4 (0.39) | CHRNB2CHRNA4KMT2AMAP4K4PDE10A | |
| SCHEMBL23603294 | 0.79 | CHRNB2 (0.57) | CHRNB2CHRNA4KMT2ACHRNB4CHRNA3 | |
| SCHEMBL18291295 | 0.79 | NR1I2 (0.46) | CHRNB2CHRNA4KMT2AOGAPDE10A | |
| SCHEMBL20249344 | 0.76 | KMT2A (0.36) | CHRNB2CHRNA4KMT2AMAP4K4PDE10A | |
| SCHEMBL24735600 | 0.75 | PDE10A (0.41) | MAP4K4PDE10A | |
| SCHEMBL20255570 | 0.75 | CHRNA7 (0.37) | CHRNB2CHRNA4KMT2AOGACHRNA7 | |
| SCHEMBL20038224 | 0.71 | CHRNB2 (0.38) | CHRNB2CHRNA4OGAPDE10ACHRNB4 | |
| SCHEMBL20038000 | 0.71 | CHRNB2 (0.38) | CHRNB2CHRNA4OGAPDE10ACHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | CHRNB2 4863/4885CHRNA4 4628/4885KMT2A 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.